Bristol-Myers Squibb Company (BMY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $129.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bristol-Myers Squibb Company (BMY) Stock Forecast
Analysts expect Bristol-Myers Squibb Company (BMY) to earn $6.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $50.23B. Of 28 analysts, 10 rate the stock Buy or Strong Buy, 17 Hold and 1 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $6.70.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.54, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 36% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 14.3% |
| Buy | 6 | 21.4% |
| Hold | 17 | 60.7% |
| Sell | 1 | 3.6% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 4.0% and revenue estimates fall 2.8%.
- Fiscal year ending Dec 31, 2026
- $6.44
- EPS consensus, revenue $50.23B
- Fiscal year ending Dec 31, 2027
- $6.70
- EPS consensus, revenue $48.80B
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $6.44 | $6.18 to $6.57 | 27 | $50.23B | $49.95B to $50.60B | 24 |
| Dec 31, 2027 | $6.70 | $5.72 to $7.56 | 28 | $48.80B | $46.94B to $50.17B | 26 |
Quarterly Estimates
The EPS consensus rises from $1.50 for the quarter ending Dec 31, 2026 to $1.52 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.50 | $1.29 to $1.69 | 25 | $12.80B | $12.17B to $13.68B | 23 |
| Mar 31, 2027 | $1.52 | $1.31 to $1.68 | 9 | $11.17B | $10.64B to $11.37B | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 20 upward and 8 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 17 | 7 |
| Quarter ending Mar 31, 2027 | 3 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 7.3% from $6.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $6.44 | $6.44 | $6.77 | $6.95 | $6.95 | -7.3% |
| Fiscal year ending Dec 31, 2027 | $6.70 | $6.66 | $6.60 | $6.56 | $6.56 | +2.2% |
| Quarter ending Mar 31, 2027 | $1.52 | $1.51 | $1.47 | $1.45 | $1.45 | +5.0% |
Frequently Asked Questions About BMY
What is the BMY stock forecast?
Consensus analyst estimates put Bristol-Myers Squibb Company's EPS at $6.44 for the fiscal year ending Dec 31, 2026, on revenue of $50.23B. The consensus rating from 28 analysts is Hold.
How do analysts rate BMY stock?
Of 28 analysts covering Bristol-Myers Squibb Company, 4 rate it Strong Buy, 6 Buy, 17 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from BMY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $6.44, with estimates from $6.18 to $6.57 from 27 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $6.70, with estimates from $5.72 to $7.56 from 28 analysts.
What revenue do analysts expect from Bristol-Myers Squibb Company next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $50.23B, with estimates from $49.95B to $50.60B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $48.80B, with estimates from $46.94B to $50.17B.
How many analysts cover BMY?
28 analysts rate Bristol-Myers Squibb Company stock, and 27 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BMY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts